Oramed Pharmaceuticals
Nadav Kidron Co-Founder & CEO
Stage: Clinical trials
Year Established: 2006
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 trials and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
20 Mamilla Ave., 3rd Floor, Jerusalem, 9414904, Israel
JLM-BIOCITY is a division of the Jerusalem Business Networking Forum (JBNF)